Emad Ibrahim, MD, Inc. | Redlands, CA
Status and phase
Conditions
Treatments
About
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients must have been diagnosed with PV according to the 2016 WHO criteria within 3 years before randomization
Patients must have JAK2V617F-positive disease
Patients with PV must meet the definition of HR for thrombosis (i.e., HR) at screening as follows:
Patients must be in need of treatment at screening, defined by the presence of at least one of the following:
Patients must have normalized HCT (i.e., HCT < 45%) at randomization
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
220 participants in 2 patient groups
Loading...
Central trial contact
Domenico Cieri
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal